China's fast-developing biopharmaceutical industry is encountering a scale-up and production bottleneck.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Poor enforcement could jeopardize China's drug innovation policy
Rights and permissions
About this article
Cite this article
Jia, H. Chinese biotech hamstrung by production issues. Nat Biotechnol 25, 147–148 (2007). https://doi.org/10.1038/nbt0207-147
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0207-147
This article is cited by
-
Innovation capacity and economic development: China and India
Economic Change and Restructuring (2011)
-
Chinese health biotech and the billion-patient market
Nature Biotechnology (2008)